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Abstracts / Urological Science 26 (2015) S1eS25 S5Conclusion: This case emphasizes the potential for stone formation when
non-absorbable sutures are used in the urinary tract. Whenwe encounter a
urolithiasis that locates over the place where a prior surgical procedure
was done, we should keep in mind to ﬁnd out any possible non-absorbable
material remains.
PD3-2:
TRPV1 HYPERFUNCTION IMPAIRS RENAL SENSORY RESPONSE IN THE
RAT HYPEROXALURIC KIDNEY
Ming-Chieh Ma 1, Ho-Shiang Huang 2. 1 School of Medicine, Fu Jen Catholic
University, New Taipei City, Taiwan; 2Department of Urology, National
Cheng Kung University, Tainan, Taiwan
Purpose: We previously demonstrated that renal sensory function in
response to mechano- and chemo-stimulationwas impaired in rat kidneys
with hyperoxaluria and/or calcium oxalate (CaOx) crystals. The transient
receptor potential vanilloid 1 channel (TRPV1) is known to present in rat
kidneys and responsible for activation of afferent renal nerve activity
(ARNA) and induction of diuretic renorenal reﬂex. The present study
therefore tests whether TRPV1 dysfunction may be the underlying
mechanism for contribution to sensory impairment seen in the hyper-
oxaluric kidney.
Materials and Methods: Acute hyperoxaluria was induced by intrapelvic
perfusion of oxalate into renal pelvis, a tissue area mostly originated for
renal sensory nerves. Chronic hyperoxaluria was induced in rats after fed
with fed with 5% hydroxyl-L-proline (HP) in daily diet for 42 days. Renal
nerves in the left kidney were carefully isolated for recording of ARNA and
efferent renal sympathetic nerve activity (ERSNA). Changes in the cortical
microvascular blood ﬂow (CMBF) weremonitored by ultrasonic ﬂowmeter.
Renorenal reﬂex response was tested by rising intrapelvic pressure (IPP) or
intrapelvic perfusion of high salt solution in the left kidney, and urine
output and sodium excretion in the contralateral (right) kidney were
collected. Renal pelvic efﬂuent was collected for determination of the
amount of sensory neuropeptide substance P (SP) release. Changes in
TRPV1 and neurokinin-1 receptor (NK-1R) expression in renal pelvis were
examined by Western blot analysis.
Results: Compared to vehicle-treated kidney, acute perfusion of oxalate
into renal pelvis resulted in persistently decreased ARNA, increased
ERSNA, decreased CMBF, and impaired renorenal reﬂex after 4 h of treat-
ment. SP release was increased after oxalate treatment, this associated
with NK-1R downregulation. These however were attenuated by co-
treatment of speciﬁc TRPV1 blocker SB-366791. As a polymodal sensor, our
results indicate TRPV1 may act as an oxalate sensor. In HP rats, ARNA in
response to chemo- and mechano-stimulation, and ARNA-mediated reﬂex
control on ERSNA and renal excretion were impaired after 7 days of
treatment and thereafter. Severe reductions were found after 42 days of
hyperoxaluria with CaOx deposition. These associated with increases in
TRPV1 expression and SP release, and NK-1R downregulation in renal
pelvis.
Conclusion: Our results clearly indicate that TRPV1 hyperfunction con-
tributes to renal sensory impairment in the hyperoxaluric rats, which led
to too much SP release, and NK-1R desensitization in nerve endings of
renal pelvis. Deﬁciency in renal sensation blinds the kidney to the presence
of hyperoxaluria as well as the formation of CaOx.
PD3-3:
MOBILIZATION OF ENDOGENOUS STEM CELLS ATTENUATES TUBULAR
CELL DAMAGE AND CALCIUM OXALATE CRYSTAL FORMATION IN THE
RAT HYPEROXALURIC KIDNEY
Ho-Shiang Huang 1, Ming-Chieh Ma 2. 1Department of Urology, National
Cheng Kung University, Tainan, Taiwan; 2 School of Medicine, Fu Jen
Catholic University, New Taipei City, Taiwan
Purpose: Cell therapy has been demonstrated to be beneﬁcial for treat-
ment of disease by enhancing self and/or endogenous repair in various
organ tissues. Whether cell therapy is effective to alleviate tubular cell
injury caused by hyperoxaluria during kidney stone formation is still un-
clear. This study aims to test whether mobilization of endogenous stemcells from bone marrow may protect kidneys against hyperoxaluria and
further calcium oxalate (CaOx) crystal deposition.
Materials and Methods: Male Wistar rats were divided into control rats
received standard diet and hyperoxaluric rats fed with 5% hydroxyl-L-
proline (HP) in daily diet for 7 and 28 days. Another group of HP rats was
received plerixafor, a selective CXCR4 blocker (AMD3100), continuously
via a subcutaneous implant of mini-osmotic pump as CXCR4 antagonism is
known to mobilize endogenous stem/progenitor cells into circulation. The
24 h of urine samplewas collected to evaluate degree of supersaturation by
estimation of the ionic activity of calcium oxalate (CaOx) and the amount
of calcium crystal excretion in urine sedimentation. Blood sample was
collected to evaluate the circulating level of CD34+CXCR4+ cells. Crystal
distribution within the kidneys will be examined by counting crystal de-
posits by von Kossa staining. Protein expressions in renal tissues and in
urine were quantitatively analyzed.
Results: Compared to the vehicle-treated HP rats, plerixafor signiﬁcantly
attenuated CaOx crystal deposition and increased the amount of urinary
sediment after 28-day treatment but without any effect on hyperoxaluria
and supersaturation at both time-points. Interestingly, circulating
CD34+CXCR4+ cells were markedly elevated in the plerixafor-treated rats
after 7 days and persisted thereafter. This was associated with an increase
in renal expression of stromal cell-derived factor 1 (SDF-1) in the plerix-
afor-treated kidneys for 7 and 28 days. The urinary contents of two anti-
crystallization molecules, osteopontin (OPN) and Tamm-Horsfall protein
(THP), in the plerixafor-treated HP rats were signiﬁcantly increased as
compared to those in the vehicle-treated HP groups for 7 and 28 days. This
associated with an attenuation of enzymuria for tubular damage markers,
a- and m-glutathione-S-transferase (GST). Moreover, renal contents of OPN,
THP, aGST, and mGST in the plerixafor-treated HP rats were higher than
those in the vehicle-treated HP groups at both time-points.
Conclusion: These results clearly indicate that the anticrystallization ef-
fect of plerixafor is possibly related to an increase in CD34+CXCR4+ cell
homing to the injured hyperoxaluric kidney with a higher SDF-1 expres-
sion, which attenuates tubular cell injury and against CaOx crystal for-
mation by maintenance of renal production of OPN and THP. Attenuation
of cell debris desquamated from damaged tubular cells may prevent
seeding effect for calcium crystal formation in growth.
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Purpose: a1 receptors and subtypes have been conﬁrmed to distribute in
human pelvis and calyces recently. As used in ureteral stones, a-blocker
treatment may facilitate kidney stone passage and long-term prescription
of a-blocker may decrease the risk of recurrent urolithiasis. The aim of this
study is to determine if use of a-blockers 180 days or more can decrease
the risk of recurrent urolithiasis needed for surgical intervention.
Materials and Methods: A representative database of 1,000,000 patients
from Taiwan's National Health Insurance was analyzed. Eligible patients
were those who had received the ﬁrst-time procedure for upper urinary
stone removal, including extracorporeal shock-wave lithotripsy, ureter-
orenoscopic lithotripsy, or both, between 2000 and 2010. After completing
a 180-day treatment for ﬁrst event, patients were prospectively followed-
up until a second set of stone procedures was performed (proxy of stone
recurrence), loss to follow-up, or end of study. The effect of percentage of
total number of days of a-blocker use on need for second set of stone
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analyzed by quartile. A nested case-control study was also performed.
Results: 1,259 patients were eligible for ﬁnal analyses. During 3,980 per-
son-years follow-up, 167 patients had recurrent urolithiasis needed for
surgical intervention. From ﬁrst to fourth quartile of drug exposure,
recurrence rates were 45.64, 47.19, 43.11, and 18.52 per 1,000 person-years.
The adjusted hazard ratio was 0.46 (95% CI ¼ 0.24 to 0.89) for the fourth
quartile (vs. quartile 1). In the nested case-control study, adjusted ORs was
0.23 (95% CI ¼ 0.10 to 0.53) in the fourth quartile (vs. quartile 1).
Conclusion: Use of a-blockers for 180 days or more decrease the risk of
recurrent urolithiasis needed for surgical intervention. In patients at
higher risk of recurent urolithiasis, long term prescription of a-blockers
might help them prevent further surgical intervention.
PD3-5:
WILL THE RISKS OF POSTOPERATIVE INFECTION BE INCREASED AFTER
URETEROSCOPIC LITHOTRIPSY FOR PATIENTS WITH MILD PYURIA
BEFORE THE OPERATION?
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Purpose: We evaluated whether the risks of postoperative infection will
be increased in patients with mild pyuria before ureteroscopic lithotripsy
(URSL) in a prospective study.
Materials and Methods: We prospectively enrolled patients receiving
URSL from 2011/5 to 2015/2. The patients with normal urine routine
(sediment WBC 5/HPF) before URSL were assigned as control, and those
with mild pyuria (sediment 5/HPF < WBC 50/HPF ) as experimental
group. Febrile UTI, patients < 18 years, pregnant, and urine sediment WBC
> 50/HPF were excluded. All patients received same protocol of preoper-
ative and postoperative antibiotics. Pre-, intra-operative, and post-opera-
tive urine routine and culture were collected. Peri-operative data were
compared. Post-operative pyuria, febrile episodes, and percentage of
emergency room visits were also compared.
Results: 140 patients were enrolled (experimental: 53, control: 87). Mean
age was 56.6 and 55.5 years, respectively. Patient's BMI, stone laterality,
stone location, and percentage of male patients were similar in both
groups. The mean stone size was 0.84cm vs. 0.76cm (p ¼ 0.243). The
operation duration was 58.8 vs. 49.2 min (p ¼ 0.022). The stone free rate
was 92.5% vs. 90.8%(p ¼ 0.235). Four out of 23 patients in experimental
group had positive pre-operative urine culture, two were E Coli, and two
Gram positive coccus. Two out of 12 patient in control group had positive
pre-operative urine culture, one was E. Coli and one was coagulase nega-
tive staphylococcus group. Two out of 33 patients had positive intra-
operative urine culture in experimental group: one pseudomonas, one
enterococcus species. One out of 46 patients had positive intra-operative
urine culture which was enterococcus species. Both pre-operative culture
and intra-operative culture didn't reach statistical signiﬁcance(p ¼ 0.398,
0.477 respectively). Two patients (3.8%) in the experiment group and none
in control group had post-operative fever but didn't reach statistical sig-
niﬁcance (p ¼ 0.068).
Conclusion: The incidence of postoperative fever increased in patients
with mild pyuria before URSL but didn't reach signiﬁcance compared to
patients with sterile urine.
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Purpose: To assess the safety of outpatient extracorporeal shock wave
lithotripsy (ESWL) in the management of patients with renal and ureteral
stones.
Materials and Methods: Between February 2012 and November 2014, 844
outpatients were treated with Outpatient ESWL at Taipei Veterans General
Hospital. 22 patients visited emergency department (ED) within 48 hours.
Stone size, stone shape (long to short axis ratio), location, total pulse of
shockwaves, stone management and urine analysis data and date before
ESWL, complications and treatment at ER and admission rate was inves-
tigated. Chi-Square and Logistic Regression analyses were used, with
p<0.05 set as the level of signiﬁcance.
Results: Of the 844 initial consecutive patients who underwent ESWL,
1095 times of ESWL was performed totally. There were 22(2%) patients
visited ED within 48 hours after ESWL. Mean Age was 54.3± 12.6 years
old; BMI was 25.9± 3.2; pre-ESWL Cr was 0.89± 2.54 mg/ml; post-
ESWL Cr was 1.04 ± 0.23 mg/ml; stone height/width ratio was
1.80± 0.57. The mean renal stone size was 12.2 ± 5.9 mm;. The mean
ureteral stone size was 6.1 ± 0.2 mm. 8 (8/379 ¼ 2.1%) patients had right
side stone, 14 (14/465 ¼ 3.0%) patients had left side stones. 16 patients
received ESWL for renal stone, 5 patients for ureter stone and 1 patient
for both. The most common complication was ﬂank pain include 16
patients (72.7%). Other complication includes hematuria (5 patients, all
from renal stone), fever (4 patients, all from renal stone), acute urinary
retention and nausea with vomiting (1 patient each). There were 12
patient received EWSL, PCNL, or URSL before. In 22 patient back to ER, 7
patients admitted to ward and 1 patient back to ER twice continuously.
All patients received medical treatment without ESWL or surgical
management.
Conclusion: The 48 hours Emergency Department Visiting rate was 2%.
There was no severe morbidity or mortality case. The tendency risk factors
according to our study include renal stone, large stone height/width ratio,
pre-ESWL stone management. The conclusion showed the outpatient
ESWL is safe for treating renal and ureteral stones.Podium-4
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PD4-1:
THE MOST IDEAL GUIDELINES FOR PERFORMING BONE SCANS IN
PROSTATE CANCER STAGING IN TAIWAN
Tsu-Ming Chien 1, Yen-Man Lu 1, Hung-Lung Ke 1,2, Shu-Pin
Huang 1,2, Chun-Nung Huang 1,2. 1Division of Urology, Kaohsiung Medical
University Hospital, Kaohsiung, Taiwan; 2 School of Medicine, Kaohsiung
Medical University, Kaohsiung, Taiwan
Purpose: The necessity of bone scans in newly diagnosed prostate cancer
patients is still a matter of debate. We attempt to evaluate the validity of
currently published guidelines by analyzing bone scan results in newly
diagnosed prostate cancer (PCa) patients to determine the optimal staging
strategies.
Materials and Methods: Between January 2011 and July 2014, there were
362 consecutive newly diagnosed PCa patients at Kaohsiung Medical
University Hospital. Bone scans were performed for all patients at initial
staging. Patients positive for bone metastasis were characterized at diag-
nosis in terms of age, prostate-speciﬁc antigen (PSA) level, Gleason score
(GS), and clinical stage. We analyzed the sensitivity and speciﬁcity of the
American Urological Association (AUA) best practice policy, European As-
sociation of Urology guidelines, National Comprehensive Cancer Network
guidelines, and the classiﬁcation and regression tree by Briganti et al. for
diagnostic performance in predicting bone metastasis.
Results: A total 73 of 362 (20.2%) patients were diagnosed with bone
metastasis. Patients positive for metastasis on bone scans had signiﬁcantly
higher PSA levels (943.6 ± 2198.4 ng/mL vs. 56.1± 183.1 ng/mL; p < 0.001)
and higher GSs (8.5± 1.0 vs. 7.0± 1.6; p < 0.001) than those with negative
bone scan results. Pairwise comparisons in receiver operating curve
